公开(公告)号：US10080741B2

公开(公告)日：2018-09-25

申请号：US15497268

申请日：2017-04-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Brett Granger ,  Ruichao Shen ,  Xuechao Xing ,  Bin Wang ,  Jun Ma ,  Jing He ,  Jiang Long ,  Yong He ,  Guoqiang Wang

IPC: C07D261/08 ,  C07D413/12 ,  A61K31/42 ,  C07D261/06 ,  C07D413/04

CPC classification number: A61K31/42 ,  C07D261/06 ,  C07D261/08 ,  C07D413/04 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US20170304271A1

公开(公告)日：2017-10-26

申请号：US15497307

申请日：2017-04-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Ruichao Shen ,  Xuechao Xing ,  Brett Granger ,  Bin Wang ,  Jun Ma ,  Jing He ,  Yong He ,  Jiang Long ,  Guoqiang Wang

IPC: A61K31/42 ,  C07D277/62 ,  C07D275/04 ,  C07D261/08 ,  A61K31/64 ,  A61K31/545 ,  A61K31/4725 ,  C07D413/12 ,  A61K31/426

CPC classification number: A61K31/42 ,  A61K31/426 ,  A61K31/4725 ,  A61K31/545 ,  A61K31/64 ,  C07D261/08 ,  C07D275/04 ,  C07D277/62 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US09765087B2

公开(公告)日：2017-09-19

申请号：US14245001

申请日：2014-04-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Ce Wang ,  Xiaowen Peng ,  Hui Cao ,  Lu Ying ,  Xuri Gao ,  Bin Wang ,  Yat Sun Or

IPC: C07D498/10 ,  C07D403/14 ,  A61K31/4184 ,  C07D401/14 ,  A61K31/444 ,  C07D405/14 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/675 ,  C07D487/08 ,  A61K31/506 ,  C07D409/14 ,  C07D413/14 ,  A61K31/422 ,  C07D491/107 ,  A61K31/517 ,  C07D417/14 ,  A61K45/06 ,  A61K38/19 ,  A61K38/21 ,  A61K31/427 ,  A61K31/7056 ,  C07F9/6558 ,  A61K31/13

CPC classification number: C07D498/10 ,  A61K31/13 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/427 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/19 ,  A61K38/21 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/08 ,  C07D491/107 ,  C07F9/65583 ,  A61K2300/00 ,  A61K39/12

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US09220748B2

公开(公告)日：2015-12-29

申请号：US14146161

申请日：2014-01-02

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Jun Ma ,  Guoqiang Wang ,  Jiang Long ,  Bin Wang

IPC: A61K38/12 ,  C07K5/097 ,  C07K5/062 ,  C07K5/083 ,  C07K5/08 ,  C07K14/81

CPC classification number: C07K5/123 ,  A61K38/00 ,  A61K38/12 ,  A61K45/06 ,  C07K5/06034 ,  C07K5/0808 ,  C07K5/0823 ,  C07K5/0827 ,  C07K14/811

Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。